Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
Kura Oncology (KURA) PT Lowered to $32 at H.C. Wainwright
November 24, 2021 10:20 AM ESTH.C. Wainwright analyst Joseph Pantginis lowered the price target on Kura Oncology (NASDAQ: KURA) to $32.00 (from $43.00) while maintaining a Buy rating.
The analyst commented, "This morning, Kura announced the FDA has placed a partial clinical hold on the KOMET-001 Phase 1b study evaluating KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML). The hold was put in place... More
